schizophrenia – media

Schizophrenia Treatment Simplified Using mHealth Tools

A pioneering mHealth program has found favor with mobile health advocates. The stated program is anticipated to be useful in the treatment of people suffering from schizophrenia spectrum disorders.
- Source: Ddu
- 632
- May 30, 2018
mHealth Researches schizophrenia
Biogen buys Pfizer’s unwanted neuro med for $75M as sell-off starts

As Pfizer clears house of its unwanted neuro assets, Biogen has become a buyer for one, namely a phase 2-ready schizophrenia drug.
- Source: FierceBiotech
- 770
- March 13, 2018
Company Insight Pfizer pharmaceutical schizophrenia
New Genes Associated With Cognitive Ability Identified

Investigators at The Feinstein Institute for Medical Research discovered dozens of new genetic variations associated with a person’s general cognitive ability. The findings, which were published online today in Cell Reports, have the potential to help researchers develop more targeted treatment for cognitive and memory disorders.
- Source: neurosciencenews
- 524
- November 29, 2017
Alzheimer's disease cognitive disorders Researches schizophrenia
How Does Schizophrenia Change Brain Structures?

Researchers compare the volumes of various regions of the brain in people with and without schizophrenia to identify the key brain structures involved.
- Source: medicalempires
- 523
- November 27, 2017
brain Researches schizophrenia
Allegoric Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the Maintenance Treatment of Schizophrenia

Allergan plc (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VRAYLAR™ (cariprazine) for the maintenance treatment of adults with schizophrenia. VRAYLAR is also approved in the U.S. in adults for the acute treatment of schizophrenia and acute treatment of manic or mixed episodes of bipolar I disorder.
- Source: Allergan
- 481
- November 24, 2017
bipolar I disorder FDA schizophrenia VRAYLAR™
US regulators approve first digital pill to track patients

US regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns. The digital pill approved Monday combines two existing products: the former blockbuster psychiatric medication Abilify—long used to treat schizophrenia and bipolar disorder—with a sensor tracking system first approved in 2012.
- Source: medicalxpress
- 513
- November 15, 2017
bipolar disorder blockbuster New Approvals psychiatric schizophrenia
EU nod for Gedeon’s novel antipsychotic Reagila

European regulators have approved Gedeon Richter’s novel antipsychotic Reagila as a new option for the treatment of patients with schizophrenia.
- Source: pharmatimes
- 485
- July 20, 2017
New Approvals Reagila schizophrenia

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.